Skip to main content
main-content

Gout and crystal arthropathies

Medications

12-12-2018 | Gout | News

Hepatotoxicity reassurance for febuxostat-treated patients with gout and fatty liver disease

Results of an observational study provide preliminary evidence suggesting that patients with gout and fatty liver disease who are treated with febuxostat do not have an elevated risk for hepatotoxicity.

Source:

J Rheumatol 2018; doi:10.3899/jrheum.180761

27-11-2018 | Gout | Article

The challenges of approaching and managing gout

Fields TR. Rheum Dis Clin North Am 2019; 45: 145–157. doi: 10.1016/j.rdc.2018.09.009

Highlights from the 2018 ACR/ARHP Annual Meeting

Editorial board members Oliver FitzGerald and Fernando Pérez-Ruiz provide their highlights from the spondyloarthropathy and crystal arthropathy sessions at the 2018 ACR/ARHP Annual Meeting in Chicago, Illinois, USA.

Gout patients may benefit from nurse-led care

Nurse-led care involving patient education and engagement increases the likelihood of achieving target serum urate levels among individuals with gout, findings from a UK randomized controlled trial suggest.

02-11-2018 | Gout | Highlight | News

Gout patients may benefit from nurse-led care

Nurse-led care involving patient education and engagement increases the likelihood of achieving target serum urate levels among individuals with gout, findings from a UK randomized controlled trial suggest.

Source:

Lancet 2018; 392: 1379–1381, 1403–1412

31-10-2018 | Psoriatic arthritis | ACR/ARHP 2018 | Article

From the Editorial Board: Highlights from the 2018 ACR/ARHP Annual Meeting

Editorial board members Oliver FitzGerald and Fernando Pérez-Ruiz provide their highlights from the spondyloarthropathy and crystal arthropathy sessions at the 2018 ACR/ARHP Annual Meeting in Chicago, Illinois, USA.

Source:

ACR/ARHP Annual Meeting; Chicago, Illinois, USA: 19–24 October 2018

Hyperuricemia and chondrocalcinosis: A clinical challenge for diagnosis and treatment

Editorial board member Fernando Pérez-Ruiz presents an interesting presentation of coexistant hyperuricemia and chondrocalcinosis, and outlines the challenges of diagnosis and management of these conditions.

18-10-2018 | Crystal arthropathies | Case report | Article

Hyperuricemia and chondrocalcinosis: A clinical challenge for diagnosis and treatment

Editorial board member Fernando Pérez-Ruiz presents an interesting presentation of coexistant hyperuricemia and chondrocalcinosis, and outlines the challenges of diagnosis and management of these conditions.

Author:
Fernando Pérez-Ruiz

11-10-2018 | Gout | Highlight | News

Allopurinol does not increase CKD risk in patients with gout

Allopurinol, given at a starting dose of at least 300 mg/day, does not increase the risk for chronic kidney disease stage 3 or higher, and may in fact reduce it, in patients with newly diagnosed gout, study data show.

Source:

JAMA Intern Med 2018; doi:10.1001/jamainternmed.2018.4463

IL-1 beta inhibition reduces gout attack risk

Administration of canakinumab, an interleukin-1β inhibitor, every 3 months is associated with a significantly reduced risk for gout, without lowering serum uric acid levels, shows a secondary exploratory analysis of the CANTOS trial.

Calcium crystal deposition diseases: Beyond gout

In this review, the main clinical manifestations of calcium pyrophosphate dihydrate and basic calcium phosphate crystal deposition are discussed, along with the biological effects of these crystals, current therapeutic approaches and future directions in therapy [read more].
McCarthy GM, Dunne A. Nat Rev Rheumatol 2018. doi: 10.1038/s41584-018-0078-5

21-09-2018 | Gout | Highlight | News

IL-1 beta inhibition reduces gout attack risk

Administration of canakinumab, an interleukin-1β inhibitor, every 3 months is associated with a significantly reduced risk for gout, without lowering serum uric acid levels, shows a secondary exploratory analysis of the CANTOS trial.

Source:

Ann Intern Med 2018; doi:10.7326/M18-1167

06-09-2018 | Calcium crystal deposition disease | Review | Article

Calcium crystal deposition diseases: Beyond gout

McCarthy GM, Dunne A. Nat Rev Rheumatol 2018. doi: 10.1038/s41584-018-0078-5

Goals of gout treatment: A patient perspective

The primary objective of this study was to perform formative work to understand and define gout treatment goals from a patient perspective, using the nominal group technique [read more].
Singh JA. Clin Rheumatol 2018; 37: 2557–2566. doi: 10.1007/s10067-018-4243-7

15-08-2018 | Gout | News

Further evidence for the benefits of febuxostat in gout patients with renal impairment

Results of a phase III trial indicate that both the immediate and extended release formulations of febuxostat reduce serum uric acid levels in patients with gout, including those with impaired renal function.

Source:

Arthritis Rheumatol 2018; doi:10.1002/art.40685

14-08-2018 | Gout | Article

Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout

Terkeltaub R et al. Rheumatology (Oxford) 2018: key245. doi: 10.1093/rheumatology/key245

09-08-2018 | Gout | Article

Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomized controlled trial

Stamp LK et al. Rheumatology (Oxford) 2018: key237. doi: 10.1093/rheumatology/key237

04-08-2018 | Gout | Article

Goals of gout treatment: A patient perspective

Singh JA. Clin Rheumatol 2018; 37: 2557–2566. doi: 10.1007/s10067-018-4243-7

image credits